Veraxa Biotech Holding AG (VRXA) Stock Competitors & Peer Comparison

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, VRTX has a market cap of 114.6B. Regarding current trading prices, VRXA is priced at $4.48, while VRTX trades at $451.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas VRTX's P/E ratio is 26.79. In terms of profitability, VRXA's ROE is N/A, compared to VRTX's ROE of +0.24%. Regarding short-term risk, VRXA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check VRTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRXA is priced at $4.48, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRXA's ROE is N/A, compared to VRNA's ROE of -0.13%. Regarding short-term risk, VRXA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check VRNA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, REGN has a market cap of 62.8B. Regarding current trading prices, VRXA is priced at $4.48, while REGN trades at $609.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas REGN's P/E ratio is 14.90. In terms of profitability, VRXA's ROE is N/A, compared to REGN's ROE of +0.14%. Regarding short-term risk, VRXA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check REGN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, VRXA is priced at $4.48, while ARGX trades at $877.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ARGX's P/E ratio is 39.03. In terms of profitability, VRXA's ROE is N/A, compared to ARGX's ROE of +0.37%. Regarding short-term risk, VRXA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ARGX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRXA is priced at $4.48, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRXA's ROE is N/A, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRXA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check SGEN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ALNY has a market cap of 37.1B. Regarding current trading prices, VRXA is priced at $4.48, while ALNY trades at $278.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ALNY's P/E ratio is 70.05. In terms of profitability, VRXA's ROE is N/A, compared to ALNY's ROE of +0.98%. Regarding short-term risk, VRXA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ALNY's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RVMDW has a market cap of 35.4B. Regarding current trading prices, VRXA is priced at $4.48, while RVMDW trades at $6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RVMDW's P/E ratio is N/A. In terms of profitability, VRXA's ROE is N/A, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, VRXA is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for VRXA.Check RVMDW's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RVMD has a market cap of 34.7B. Regarding current trading prices, VRXA is priced at $4.48, while RVMD trades at $162.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RVMD's P/E ratio is -22.92. In terms of profitability, VRXA's ROE is N/A, compared to RVMD's ROE of -0.83%. Regarding short-term risk, VRXA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RVMD's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MRNA has a market cap of 25.4B. Regarding current trading prices, VRXA is priced at $4.48, while MRNA trades at $63.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MRNA's P/E ratio is -7.86. In terms of profitability, VRXA's ROE is N/A, compared to MRNA's ROE of -0.37%. Regarding short-term risk, VRXA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MRNA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, VRXA is priced at $4.48, while BNTX trades at $90.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BNTX's P/E ratio is -15.46. In terms of profitability, VRXA's ROE is N/A, compared to BNTX's ROE of -0.07%. Regarding short-term risk, VRXA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BNTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RPRX has a market cap of 22.8B. Regarding current trading prices, VRXA is priced at $4.48, while RPRX trades at $52.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RPRX's P/E ratio is 27.87. In terms of profitability, VRXA's ROE is N/A, compared to RPRX's ROE of +0.13%. Regarding short-term risk, VRXA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RPRX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, VRXA is priced at $4.48, while UTHR trades at $536.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas UTHR's P/E ratio is 19.85. In terms of profitability, VRXA's ROE is N/A, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRXA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check UTHR's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ROIV has a market cap of 22.6B. Regarding current trading prices, VRXA is priced at $4.48, while ROIV trades at $31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ROIV's P/E ratio is -58.20. In terms of profitability, VRXA's ROE is N/A, compared to ROIV's ROE of -0.07%. Regarding short-term risk, VRXA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ROIV's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, VRXA is priced at $4.48, while INSM trades at $95.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas INSM's P/E ratio is -16.63. In terms of profitability, VRXA's ROE is N/A, compared to INSM's ROE of -1.30%. Regarding short-term risk, VRXA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check INSM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRXA is priced at $4.48, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRXA's ROE is N/A, compared to BGNE's ROE of +0.12%. Regarding short-term risk, VRXA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BGNE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, VRXA is priced at $4.48, while INCY trades at $98.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas INCY's P/E ratio is 13.87. In terms of profitability, VRXA's ROE is N/A, compared to INCY's ROE of +0.29%. Regarding short-term risk, VRXA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check INCY's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRXA is priced at $4.48, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRXA's ROE is N/A, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, VRXA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check DNA-WT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, NBIX has a market cap of 15.9B. Regarding current trading prices, VRXA is priced at $4.48, while NBIX trades at $158.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas NBIX's P/E ratio is 24.31. In terms of profitability, VRXA's ROE is N/A, compared to NBIX's ROE of +0.22%. Regarding short-term risk, VRXA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check NBIX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, GMAB has a market cap of 15.5B. Regarding current trading prices, VRXA is priced at $4.48, while GMAB trades at $25.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas GMAB's P/E ratio is 19.29. In terms of profitability, VRXA's ROE is N/A, compared to GMAB's ROE of +0.15%. Regarding short-term risk, VRXA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check GMAB's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, VRXA is priced at $4.48, while ASND trades at $230.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ASND's P/E ratio is 26.29. In terms of profitability, VRXA's ROE is N/A, compared to ASND's ROE of -56.42%. Regarding short-term risk, VRXA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ASND's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, JAZZ has a market cap of 14.1B. Regarding current trading prices, VRXA is priced at $4.48, while JAZZ trades at $224.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas JAZZ's P/E ratio is 2042.36. In terms of profitability, VRXA's ROE is N/A, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, VRXA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check JAZZ's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, VRXA is priced at $4.48, while EXEL trades at $51.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas EXEL's P/E ratio is 17.19. In terms of profitability, VRXA's ROE is N/A, compared to EXEL's ROE of +0.40%. Regarding short-term risk, VRXA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check EXEL's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, VRXA is priced at $4.48, while BBIO trades at $66.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BBIO's P/E ratio is -17.72. In terms of profitability, VRXA's ROE is N/A, compared to BBIO's ROE of +0.36%. Regarding short-term risk, VRXA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BBIO's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, AXSM has a market cap of 12.9B. Regarding current trading prices, VRXA is priced at $4.48, while AXSM trades at $250.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas AXSM's P/E ratio is -67.16. In terms of profitability, VRXA's ROE is N/A, compared to AXSM's ROE of -2.60%. Regarding short-term risk, VRXA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check AXSM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRXA is priced at $4.48, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRXA's ROE is N/A, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRXA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check KRTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, VRXA is priced at $4.48, while IONS trades at $74.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas IONS's P/E ratio is -36.88. In terms of profitability, VRXA's ROE is N/A, compared to IONS's ROE of -0.59%. Regarding short-term risk, VRXA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check IONS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, VRXA is priced at $4.48, while MDGL trades at $505.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MDGL's P/E ratio is -37.52. In terms of profitability, VRXA's ROE is N/A, compared to MDGL's ROE of -0.50%. Regarding short-term risk, VRXA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MDGL's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ARWR has a market cap of 11.5B. Regarding current trading prices, VRXA is priced at $4.48, while ARWR trades at $81.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ARWR's P/E ratio is -36.04. In terms of profitability, VRXA's ROE is N/A, compared to ARWR's ROE of -0.55%. Regarding short-term risk, VRXA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ARWR's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRXA is priced at $4.48, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRXA's ROE is N/A, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRXA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RNAM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, VRXA is priced at $4.48, while SMMT trades at $13.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas SMMT's P/E ratio is -8.65. In terms of profitability, VRXA's ROE is N/A, compared to SMMT's ROE of -3.41%. Regarding short-term risk, VRXA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check SMMT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, VRXA is priced at $4.48, while BMRN trades at $54.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BMRN's P/E ratio is 39.35. In terms of profitability, VRXA's ROE is N/A, compared to BMRN's ROE of +0.04%. Regarding short-term risk, VRXA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BMRN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, VRXA is priced at $4.48, while KRYS trades at $348.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas KRYS's P/E ratio is 46.53. In terms of profitability, VRXA's ROE is N/A, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRXA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check KRYS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, VRXA is priced at $4.48, while CYTK trades at $78.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CYTK's P/E ratio is -11.50. In terms of profitability, VRXA's ROE is N/A, compared to CYTK's ROE of +1.40%. Regarding short-term risk, VRXA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CYTK's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRXA is priced at $4.48, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRXA's ROE is N/A, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRXA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RXDX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VRXA is priced at $4.48, while NUVL trades at $123.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas NUVL's P/E ratio is -20.37. In terms of profitability, VRXA's ROE is N/A, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VRXA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check NUVL's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, VRXA is priced at $4.48, while TECH trades at $57.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas TECH's P/E ratio is 82.77. In terms of profitability, VRXA's ROE is N/A, compared to TECH's ROE of +0.05%. Regarding short-term risk, VRXA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check TECH's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRXA is priced at $4.48, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRXA's ROE is N/A, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRXA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check IMGN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, VRXA is priced at $4.48, while CORT trades at $79.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CORT's P/E ratio is 228.31. In terms of profitability, VRXA's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, VRXA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CORT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRXA is priced at $4.48, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRXA's ROE is N/A, compared to BPMC's ROE of -0.15%. Regarding short-term risk, VRXA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BPMC's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRXA is priced at $4.48, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRXA's ROE is N/A, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRXA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CERE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, TGTX has a market cap of 8.1B. Regarding current trading prices, VRXA is priced at $4.48, while TGTX trades at $53.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas TGTX's P/E ratio is 18.61. In terms of profitability, VRXA's ROE is N/A, compared to TGTX's ROE of +0.87%. Regarding short-term risk, VRXA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check TGTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, VRXA is priced at $4.48, while HALO trades at $68.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas HALO's P/E ratio is 24.05. In terms of profitability, VRXA's ROE is N/A, compared to HALO's ROE of +1.26%. Regarding short-term risk, VRXA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check HALO's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, IBRX has a market cap of 7.7B. Regarding current trading prices, VRXA is priced at $4.48, while IBRX trades at $7.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas IBRX's P/E ratio is -8.66. In terms of profitability, VRXA's ROE is N/A, compared to IBRX's ROE of +1.39%. Regarding short-term risk, VRXA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check IBRX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ALKS has a market cap of 7.5B. Regarding current trading prices, VRXA is priced at $4.48, while ALKS trades at $44.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ALKS's P/E ratio is 49.99. In terms of profitability, VRXA's ROE is N/A, compared to ALKS's ROE of +0.09%. Regarding short-term risk, VRXA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ALKS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, KYMR has a market cap of 7.4B. Regarding current trading prices, VRXA is priced at $4.48, while KYMR trades at $90.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas KYMR's P/E ratio is -25.26. In terms of profitability, VRXA's ROE is N/A, compared to KYMR's ROE of -0.25%. Regarding short-term risk, VRXA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check KYMR's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRXA is priced at $4.48, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRXA's ROE is N/A, compared to MTSR's ROE of -0.80%. Regarding short-term risk, VRXA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MTSR's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, VRXA is priced at $4.48, while PCVX trades at $51.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas PCVX's P/E ratio is -7.47. In terms of profitability, VRXA's ROE is N/A, compared to PCVX's ROE of -0.33%. Regarding short-term risk, VRXA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check PCVX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, PTGX has a market cap of 7.3B. Regarding current trading prices, VRXA is priced at $4.48, while PTGX trades at $112.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas PTGX's P/E ratio is -62.35. In terms of profitability, VRXA's ROE is N/A, compared to PTGX's ROE of -0.18%. Regarding short-term risk, VRXA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check PTGX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, VRXA is priced at $4.48, while IMVT trades at $35.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas IMVT's P/E ratio is -12.76. In terms of profitability, VRXA's ROE is N/A, compared to IMVT's ROE of -0.68%. Regarding short-term risk, VRXA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check IMVT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRXA is priced at $4.48, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRXA's ROE is N/A, compared to MRUS's ROE of -0.51%. Regarding short-term risk, VRXA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MRUS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRXA is priced at $4.48, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VRXA's ROE is N/A, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRXA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ACLX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, VRXA is priced at $4.48, while RYTM trades at $96.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RYTM's P/E ratio is -30.92. In terms of profitability, VRXA's ROE is N/A, compared to RYTM's ROE of -2.03%. Regarding short-term risk, VRXA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RYTM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRXA is priced at $4.48, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRXA's ROE is N/A, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRXA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RETA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, PTCT has a market cap of 6.6B. Regarding current trading prices, VRXA is priced at $4.48, while PTCT trades at $78.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas PTCT's P/E ratio is -31.09. In terms of profitability, VRXA's ROE is N/A, compared to PTCT's ROE of +1.00%. Regarding short-term risk, VRXA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check PTCT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, VRXA is priced at $4.48, while ABVX trades at $99.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ABVX's P/E ratio is -18.53. In terms of profitability, VRXA's ROE is N/A, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VRXA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ABVX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, VRXA is priced at $4.48, while LQDA trades at $71.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas LQDA's P/E ratio is 418.06. In terms of profitability, VRXA's ROE is N/A, compared to LQDA's ROE of +0.47%. Regarding short-term risk, VRXA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check LQDA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, VRXA is priced at $4.48, while CNTA trades at $40.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CNTA's P/E ratio is -22.48. In terms of profitability, VRXA's ROE is N/A, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VRXA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CNTA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, PRAX has a market cap of 6B. Regarding current trading prices, VRXA is priced at $4.48, while PRAX trades at $282.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas PRAX's P/E ratio is -21.07. In terms of profitability, VRXA's ROE is N/A, compared to PRAX's ROE of -0.43%. Regarding short-term risk, VRXA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check PRAX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, VRXA is priced at $4.48, while COGT trades at $34.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas COGT's P/E ratio is -15.92. In terms of profitability, VRXA's ROE is N/A, compared to COGT's ROE of -0.83%. Regarding short-term risk, VRXA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check COGT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, VRXA is priced at $4.48, while BLTE trades at $146.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BLTE's P/E ratio is -57.53. In terms of profitability, VRXA's ROE is N/A, compared to BLTE's ROE of -0.27%. Regarding short-term risk, VRXA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BLTE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, VRXA is priced at $4.48, while SRRK trades at $47.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas SRRK's P/E ratio is -13.72. In terms of profitability, VRXA's ROE is N/A, compared to SRRK's ROE of -1.64%. Regarding short-term risk, VRXA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check SRRK's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRXA is priced at $4.48, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRXA's ROE is N/A, compared to CDTX's ROE of -0.60%. Regarding short-term risk, VRXA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CDTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, APGE has a market cap of 5.6B. Regarding current trading prices, VRXA is priced at $4.48, while APGE trades at $90.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas APGE's P/E ratio is -20.87. In terms of profitability, VRXA's ROE is N/A, compared to APGE's ROE of -0.33%. Regarding short-term risk, VRXA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check APGE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRXA is priced at $4.48, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRXA's ROE is N/A, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRXA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ABCM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRXA is priced at $4.48, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRXA's ROE is N/A, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRXA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ISEE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, LGND has a market cap of 5.5B. Regarding current trading prices, VRXA is priced at $4.48, while LGND trades at $274.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas LGND's P/E ratio is 35.84. In terms of profitability, VRXA's ROE is N/A, compared to LGND's ROE of +0.16%. Regarding short-term risk, VRXA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check LGND's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, VRXA is priced at $4.48, while CGON trades at $61.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CGON's P/E ratio is -26.10. In terms of profitability, VRXA's ROE is N/A, compared to CGON's ROE of -0.23%. Regarding short-term risk, VRXA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CGON's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, VRXA is priced at $4.48, while MIRM trades at $107.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MIRM's P/E ratio is -7.88. In terms of profitability, VRXA's ROE is N/A, compared to MIRM's ROE of -2.89%. Regarding short-term risk, VRXA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MIRM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, SYRE has a market cap of 5.3B. Regarding current trading prices, VRXA is priced at $4.48, while SYRE trades at $88.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas SYRE's P/E ratio is -41.67. In terms of profitability, VRXA's ROE is N/A, compared to SYRE's ROE of -0.31%. Regarding short-term risk, VRXA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check SYRE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, VRXA is priced at $4.48, while FBIOX trades at $26.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas FBIOX's P/E ratio is N/A. In terms of profitability, VRXA's ROE is N/A, compared to FBIOX's ROE of N/A. Regarding short-term risk, VRXA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check FBIOX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VRXA is priced at $4.48, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, VRXA's ROE is N/A, compared to APLS's ROE of +0.40%. Regarding short-term risk, VRXA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check APLS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, VRXA is priced at $4.48, while CAI trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CAI's P/E ratio is -6.69. In terms of profitability, VRXA's ROE is N/A, compared to CAI's ROE of +0.06%. Regarding short-term risk, VRXA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CAI's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, VRXA is priced at $4.48, while CRSP trades at $54.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CRSP's P/E ratio is -8.77. In terms of profitability, VRXA's ROE is N/A, compared to CRSP's ROE of -0.31%. Regarding short-term risk, VRXA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CRSP's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, VRXA is priced at $4.48, while LEGN trades at $27.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas LEGN's P/E ratio is -20.24. In terms of profitability, VRXA's ROE is N/A, compared to LEGN's ROE of -0.25%. Regarding short-term risk, VRXA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check LEGN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, VRXA is priced at $4.48, while TVTX trades at $55.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas TVTX's P/E ratio is -110.30. In terms of profitability, VRXA's ROE is N/A, compared to TVTX's ROE of -0.27%. Regarding short-term risk, VRXA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check TVTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VRXA is priced at $4.48, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, VRXA's ROE is N/A, compared to TERN's ROE of -0.20%. Regarding short-term risk, VRXA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check TERN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRXA is priced at $4.48, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VRXA's ROE is N/A, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRXA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check FOLD's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRXA is priced at $4.48, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRXA's ROE is N/A, compared to AKRO's ROE of -0.31%. Regarding short-term risk, VRXA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check AKRO's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRXA is priced at $4.48, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRXA's ROE is N/A, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRXA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ALPN's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, VRXA is priced at $4.48, while CELC trades at $87.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CELC's P/E ratio is -22.50. In terms of profitability, VRXA's ROE is N/A, compared to CELC's ROE of -2.45%. Regarding short-term risk, VRXA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CELC's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, VCYT has a market cap of 4.3B. Regarding current trading prices, VRXA is priced at $4.48, while VCYT trades at $53.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas VCYT's P/E ratio is 49.66. In terms of profitability, VRXA's ROE is N/A, compared to VCYT's ROE of +0.07%. Regarding short-term risk, VRXA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check VCYT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, VRXA is priced at $4.48, while ERAS trades at $13.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ERAS's P/E ratio is -14.70. In terms of profitability, VRXA's ROE is N/A, compared to ERAS's ROE of -0.77%. Regarding short-term risk, VRXA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ERAS's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRXA is priced at $4.48, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRXA's ROE is N/A, compared to OPT's ROE of +1.09%. Regarding short-term risk, VRXA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check OPT's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, VRXA is priced at $4.48, while XENE trades at $52.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas XENE's P/E ratio is -11.26. In terms of profitability, VRXA's ROE is N/A, compared to XENE's ROE of -0.49%. Regarding short-term risk, VRXA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check XENE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, KNSA has a market cap of 4.1B. Regarding current trading prices, VRXA is priced at $4.48, while KNSA trades at $55.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas KNSA's P/E ratio is 60.56. In terms of profitability, VRXA's ROE is N/A, compared to KNSA's ROE of +0.13%. Regarding short-term risk, VRXA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check KNSA's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRXA is priced at $4.48, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRXA's ROE is N/A, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRXA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MRTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, VRXA is priced at $4.48, while EWTX trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas EWTX's P/E ratio is -22.17. In terms of profitability, VRXA's ROE is N/A, compared to EWTX's ROE of -0.33%. Regarding short-term risk, VRXA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check EWTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, MANE has a market cap of 3.9B. Regarding current trading prices, VRXA is priced at $4.48, while MANE trades at $93.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas MANE's P/E ratio is -35.42. In terms of profitability, VRXA's ROE is N/A, compared to MANE's ROE of -0.95%. Regarding short-term risk, VRXA is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check MANE's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, VRXA is priced at $4.48, while CPRX trades at $31.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CPRX's P/E ratio is 18.14. In terms of profitability, VRXA's ROE is N/A, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRXA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CPRX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, VRXA is priced at $4.48, while CRNX trades at $35.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CRNX's P/E ratio is -6.98. In terms of profitability, VRXA's ROE is N/A, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VRXA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CRNX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRXA is priced at $4.48, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRXA's ROE is N/A, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRXA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check RYZB's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRXA is priced at $4.48, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRXA's ROE is N/A, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRXA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check CBAY's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, VRXA is priced at $4.48, while ACAD trades at $21.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas ACAD's P/E ratio is 9.78. In terms of profitability, VRXA's ROE is N/A, compared to ACAD's ROE of +0.36%. Regarding short-term risk, VRXA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check ACAD's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, VRXA is priced at $4.48, while DNLI trades at $23.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas DNLI's P/E ratio is -8.09. In terms of profitability, VRXA's ROE is N/A, compared to DNLI's ROE of -0.52%. Regarding short-term risk, VRXA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check DNLI's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRXA is priced at $4.48, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRXA's ROE is N/A, compared to SWTX's ROE of -0.36%. Regarding short-term risk, VRXA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check SWTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, VRXA is priced at $4.48, while VKTX trades at $30.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas VKTX's P/E ratio is -7.32. In terms of profitability, VRXA's ROE is N/A, compared to VKTX's ROE of -0.71%. Regarding short-term risk, VRXA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check VKTX's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, NAMSW has a market cap of 3.5B. Regarding current trading prices, VRXA is priced at $4.48, while NAMSW trades at $18.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas NAMSW's P/E ratio is N/A. In terms of profitability, VRXA's ROE is N/A, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, VRXA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check NAMSW's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, BEAM has a market cap of 3.5B. Regarding current trading prices, VRXA is priced at $4.48, while BEAM trades at $34.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas BEAM's P/E ratio is -69.67. In terms of profitability, VRXA's ROE is N/A, compared to BEAM's ROE of -0.06%. Regarding short-term risk, VRXA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check BEAM's competition here

VRXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VRXA stands at 610.7M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, VRXA is priced at $4.48, while NAMS trades at $29.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VRXA currently has a P/E ratio of -8.78, whereas NAMS's P/E ratio is -16.76. In terms of profitability, VRXA's ROE is N/A, compared to NAMS's ROE of -0.30%. Regarding short-term risk, VRXA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for VRXA.Check NAMS's competition here